BioXcel Therapeutics, Inc. (NASDAQ: BTAI), a pioneering biopharmaceutical company specializing in artificial intelligence-driven drug development, has made a substantial addition to its intellectual property (IP) portfolio. The contact Patent Office granted Patent No. 3,562,486 on March 13, 2024, which covers a multitude of sublingual dosage forms for BioXcel’s dexmedetomidine treatment targeting agitation in dementia patients. These dosage forms include films, wafers, and tablets.
contact Patent Marks a Milestone for BioXcel’s Dementia Treatment
This contact patent is an essential expansion to BioXcel’s extensive IP portfolio, which boasts over 100 patent applications under prosecution and numerous issued patents. “The 486 patent aligns with our strategic focus on fortifying our patent position for BXCL501 in Europe,” commented Vimal Mehta, Ph.D., the CEO of BioXcel Therapeutics. The company believes this strengthens their foundation for potential commercialization in various geographies, subject to regulatory approval.
The contact patent builds upon recent accomplishments, including the allowance of a US patent application for a water-soluble oromucosal administration of dexmedetomidine for treating agitation in Alzheimer’s disease patients. Additionally, the US Patent and Trademark Office granted a patent application for a method of treating agitation utilizing an oromucosal formulation of dexmedetomidine, expected to extend protection for BioXcel’s IGALMI™ sublingual film until January 12, 2043.
IGALMI™: Sublingual Film for Agitation Management
IGALMI™, a sublingual film formulation of dexmedetomidine, is currently FDA-approved for the acute treatment of agitation associated with schizophrenia and bipolar disorder I or II in adults. It is administered under healthcare provider supervision, and its safety and efficacy beyond 24 hours from the initial dose have not been thoroughly studied. The most common side effects reported in clinical trials include somnolence, dizziness, and hypotension.
BXCL501: Targeting Agitation across Neuropsychiatric Disorders with ai
BioXcel’s BXCL501 is an investigational film formulation of dexmedetomidine, designed to address agitation across multiple neuropsychiatric disorders. It has received Breakthrough Therapy designation for the acute treatment of agitation associated with dementia and Fast Track designation for treating agitation related to schizophrenia, bipolar disorders, and dementia.
As a progressive biopharmaceutical firm harnessing artificial intelligence in drug development, BioXcel Therapeutics is leading the charge in innovative approaches to unmet medical needs. The company’s commitment to expanding its IP portfolio and pursuing regulatory approvals for its investigational therapies underscores their dedication to advancing patient care.
The granting of the contact patent for BioXcel Therapeutics’ dementia treatment signifies a significant milestone in the company’s IP strategy and their ongoing efforts to develop novel therapies for neuropsychiatric disorders. With a robust patent portfolio and promising investigational products like BXCL501, BioXcel is well-positioned to drive innovation and potentially commercialize its treatments in various global markets, contingent on regulatory approvals.
